Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines

Vaccine

Volumn 32, Issue 26, 2014, Pages 3336-3340

  Chit, Ayman ^a   Parker, Jayson ^a   Halperin, Scott A ^b   Papadimitropoulos, Manny ^a,c   Krahn, Murray ^a   Grootendorst, Paul ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Biologic; Clinical trial; Cost; Drug development; Economics; Influenza; Research and development; Risk; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; DRUG COST; DRUG DEVELOPMENT; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA;

BIOLOGIC; CLINICAL TRIAL; COST; DRUG DEVELOPMENT; ECONOMICS; INFLUENZA; RESEARCH AND DEVELOPMENT; RISK; VACCINE;

CANADA; CAPITAL EXPENDITURES; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; HUMANS; INFLUENZA VACCINES; MODELS, ECONOMIC; REPRODUCIBILITY OF RESULTS; RESEARCH;

EID: 84900417124     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.055     Document Type: Article

References (25)

1. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22:151-185.
2. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9:203-213.
3. Light D.W., Warburton R. Demythologizing the high costs of pharmaceutical research. BioSocieties 2011, 6:34-50.
4. Morgan S., Grootendorst P., Lexchin J., Cunningham C., Greyson D. The cost of drug development: a systematic review. Health Policy 2011, 100:4-17.
5. Adams C.P., Brantner V.V. Spending on new drug development. Health Econ 2010, 19(2):130-141.
6. Talbot K.H., Griffin M.R., Chen Q., Zhu Y., Williams J., Edwards K.M. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011, 203(4):500-508.
7. Molinari N.M., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
8. Lambert L.C., Fauci M.D. Influenza vaccines for the future. N Engl J Med 2010, 363:2036-2044.
9. Dimasi J.A. Cost of innovation in the pharmaceutical industry. J Health Econ 1991, 10:107-142.
10. Harrington SE. Cost of capital for pharmaceutical, biotechnology, and medical device firms (November 13, 2009). Available at SSRN: or. doi:10.2139/ssrn.1512938.
11. DiMasi J.A., Grabowski H.G. The cost of biopharmaceutical R&D: is biotech different?. Managerial Decision Econom 2007, 28:469-479.
12. Guidelines for the economic evaluation of health technologies: Canada 2006, Canadian Agency for Drugs and Technologies in Health, Ottawa. 3rd ed.
13. Light D.W., Andrus J.K., Warburton R.N. Estimated research and development costs of rotavirus vaccines. Vaccine 2009, 27:6227-6633.
14. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program [Internet]. Canada Revenue Agency. [accessed 21.05.12]. http://www.cra-arc.gc.ca/sred/.
15. Citeline [Internet]. Trialtrove product line. [accessed 21.05.12]. http://www.citeline.com/products/trialtrove/.
16. Thomas K.B., Tesch C. Clinical trial disclosure: the ongoing debate on public registers for clinical trials. J Eur Med Writers Assoc 2007, 16:67-72.
17. CCfV [Internet]. Canadian Center for Vaccinology. [accessed 21.05.12]. http://www.centerforvaccinology.ca/.
18. PCIRN [Internet]. PHAC/CIHR Influenza Research Network. [accessed 21.05.12]. http://www.pcirn.ca/.
19. Klein J.P., Moeschberger M.L. Survival analysis techniques for censored and truncated data 2010, Springer Science and Business Media Inc. 2nd ed.
20. Light D.W. Misleading congress about drug development. J Health Polit Policy Law 2007, 32:895-913.
21. DiMasi J.A., Hansen R.W., Grabowski H.G. Misleading congress about drug development: reply. J Health Polit Policy Law 2008, 33:319-324.
22. André F.E. How the research-based industry approaches vaccine development and establishes priorities. Dev Biol 2002, 110:25-29.
23. Parker J.L., Kohler J.C. The success of new drug development in clinical trials: Crohn's disease. J Pharm Pharm Sci 2010, 13(2):191-197.
24. Osborne B.J., Kaul R., Parker J.L. Drug development risk in HIV-1 clinical trials: the effect of drug class. J Pharm Health Serv Res 2011, 2:211-216.
25. Parker J.L., Zhang Z.Y., Buckstein R. Clinical trial risk in non-Hodgkin's lymphoma: endpoint and target selection. J Pharm Pharm Sci 2011, 14(2):227-235.